Tag Archives: patent

Patently Biotech’s Top Articles of 2014

shutterstock_26191726

It’s been a whirlwind year for IP. From international trade negotiations, to revised PTO guidelines and dropping patent case stats, intellectual property is on the brain and in the news. Here are Patently Biotech’s top blog posts of 2014: TPP and IP: The Economic Benefits of a Pacific Trade Agreement Should the USPTO allow the patenting of living organisms? Gene Patent Questions Remain: USPTO Issues Examiner Guidelines Stopped at the Threshold: A New Study Reports Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

BIO Coalition Submits Patent Reform Letter to Congress

medical_research

BIO, alongside a coalition of patent holders and inventors, submitted a letter to the chairmen and ranking members of the House and Senate Judiciary Committees on December 10 regarding potential changes to the patent system. The coalition thanked members of the committee for their work to develop reforms which would prevent harmful patent enforcement practices, and once again reiterated their opposition to any legislation that would weaken the overall patent system. They also asked that Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , , , , , , , , ,

New Report Emphasizes the Role of Patent Protection in the Global Diffusion of New Drugs

medical_research

A new report from the National Bureau of Economic Research (NBER) has determined that strong patent protection accelerates the speed at which new drugs are launched in different countries. Providing affordable access is often challenged by the need to provide adequate incentives for developing new drugs, and ensuring affordable prices once they develop. Often neglected in the larger debate is that the speed at which drugs are launched and adopted in new countries is one Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , ,

BIO Submits Joint Supplemental Comments on the USPTO March Guidance

Supreme Court

Last week BIO, alongside a number of member companies and private individuals, submitted supplemental comments to the U.S. Patent and Trademark Office concerning their March 2014 Guidance on patent subject matter eligibility. In July, BIO and international bio-industry associations had submitted comments to the USPTO expressing concern about the Guidance, and its impact on the patent eligibility of biotechnology inventions. Since July, USPTO staff has indicated a final revision to the Guidance would be released Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , , , , , , , , , , , ,

Patent Cases Down by 40% in 2014

Patent-Case-Filings-by-Month-2011-20141

The number of new patent cases filed in federal court has dropped by an astonishing 40 percent as compared to this time last year. This trend has some questioning whether Congressional patent reform is even necessary. Some legal experts are attributing this drop to the fallout from the U.S. Supreme Court’s recent Alice vs. CLS Bank decision. In June, SCOTUS ruled in the case of Alice that certain subject matter which had been patentable (a computer-implemented Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , , , , , , , , , , ,